Psychedelics


Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

August 14th, 2020 - Ryan Allway

August 14, 2020 08:44 ET | Source: Revive Therapeutics Ltd. TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a Memorandum of […]

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

August 14th, 2020 - Ryan Allway

Published: Aug 14, 2020 NEW YORK, Aug. 14, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for […]

MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

August 13th, 2020 - Ryan Allway

BASEL, Switzerland, Aug. 13, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF) is expanding its presence in Europe. The leading neuro-pharmaceutical company for psychedelic inspired medicines will open an operating subsidiary in Switzerland that will oversee clinical development, scientific collaborations and the expansion of MindMed’s business in Europe. As part of the ramp up and planning process for its growing global […]

Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD

August 13th, 2020 - Ryan Allway

DENVER, Aug. 13, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD). Conducted in […]

Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector

August 12th, 2020 - Ryan Allway

Successfully Launched World’s First Psilocybin Clinical Trials Initiative for PTSD DENVER, Aug. 12, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” “MIG” or the “Company”), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position Mydecine as a genuine leader in […]

Pilze zu Pillen: Wie Psychedelika auf den Markt kommen werden

August 11th, 2020 - Ryan Allway

Psychedelika so wie Psilocybin haben eine lange Geschichte der medizinischen Anwendung. In den 1950er Jahren wurden Psychedelika für kurze Zeit in der Psychologie und Psychiatrie geschätzt, bevor ein gesetzliches Verbot Mitte der 1960er Jahre die Forschung stoppte. In den 1990er Jahren gab es erneut Forschungsinteresse, aber erst mit der Legalisierung von Cannabis ging es wieder […]

PharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the Netherlands

August 11th, 2020 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – August 11, 2020) –  PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) (“Super Smart“) has entered into a definitive agreement to acquire (the “Acquisition“) a retail establishment specializing in the sale of psychedelic […]

REVIVE THERAPEUTICS ADVANCING DRUG DELIVERY TECHNOLOGY FOR PSYCHEDELICS

August 11th, 2020 - Ryan Allway

Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin TORONTO, Aug. 11, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further to its press release […]

Mushrooms to Pills: How Psychedelic Drugs Will Come to Market

August 11th, 2020 - Ryan Allway

Psychedelic drugs, such as psilocybin, have a long history of medicinal use. In the 1950s, psychedelics had a short-lived relationship with psychology and psychiatry before a legislative ban in the mid-1960s halted research. The 1990s saw renewed research interest but it wasn’t until the legalization of cannabis that things really took off again. The next […]

GRAPH BLOCKCHAIN ENTERS INTO A BINDING LETTER OF INTENT TO ACQUIRE THIRD EYE INSIGHTS CORP

August 7th, 2020 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – August 6, 2020) – Graph Blockchain Inc. (CSE: GBLC) (“Graph” or the “Company“) announces it has entered into a binding letter of intent (“LOI”) in connection with the proposed acquisition of Third Eye Insights Corp. (“Third Eye” or “Seller”), to acquire 100% of all issued and outstanding shares of Third Eye (the “Third Eye […]

Nutritional High Announces Settlement of Payables and Update on Psychedelic Sciences Corp Acquisition.

August 6th, 2020 - Ryan Allway

Nutritional High International Inc. (EAT) (OTC Pink: SPLIF) (“Nutritional High” or the “Company“) is pleased to announce settlement of trade payables and an update regarding the acquisition of Psychedelic Sciences Corp (“PSC“). The Company announces that trade creditors representing CAD $1,159,936 have entered into settlement agreements with the Company to convert such amounts owed into 44,253,582 Units […]

Red Light Holland Commences Magic Truffles Growth Operation in the Netherlands, Months Ahead of Schedule

August 6th, 2020 - Ryan Allway

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a its brand of magic truffles to the legal, recreational market within the Netherlands (initially, in the form of its previously announced Microdosing Packs), is pleased to announce […]

NeonMind Submits Application for Psilocybin Research to Health Canada

August 6th, 2020 - Ryan Allway

The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (FE:YG3) majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) announces submission of an application to Health Canada for an exemption to use a controlled substance for scientific purposes, pursuant to Section 56(1) of the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (a “Section 56 Exemption”) for NeonMind’s planned preclinical trial using […]

Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent

August 6th, 2020 - Ryan Allway

Mindset Pharma (“Mindset”), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a provisional patent application with the USPTO for a groundbreaking process to synthesize psilocybin and psilocin—two of the known active compounds in psychedelic mushrooms. Currently, high-quality psilocybin for research purposes is expensive and difficult to procure. […]

MINDMED ADDS PSYCHEDELIC ASSISTED THERAPY EXPERT DR. PETER GASSER AS CLINICAL ADVISOR FOR PROJECT LUCY

August 6th, 2020 - Ryan Allway

Applauds Health Canada’s Approval Of Psilocybin Compassionate Access For Patients NEW YORK, Aug. 6, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy. Dr. Gasser has pioneered the legal, medical use of psychedelics through […]

4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970’s

August 5th, 2020 - Ryan Allway

Four Canadians battling incurable cancer have been approved by the Minister of Health, Patty Hajdu, to use psilocybin therapy in the treatment of their end-of-life distress. These 4 patients mark the first publicly-known individuals to receive a legal exemption from the Canadian Drugs and Substances Act to access psychedelic therapy, and the first known patients […]

OSOYOOS CLOSES NON-BROKERED PRIVATE PLACEMENT

August 4th, 2020 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – August 4, 2020) – Osoyoos Cannabis Inc. (CSE: OSO) (“Osoyoos” or the “Company”) is pleased to announce that the Company has closed its previously announced non-brokered private placement (the “Private Placement“) of up to 20,000,000 units of the Company (the “Units“), at a price of $0.05 per Unit, for gross proceeds […]

MINDLEAP HEALTH(TM) EXPANDS ITS DIGITAL MENTAL HEALTH PROGRAMS FOR ADDICTION, PSYCHEDELIC INTEGRATION AND HOLISTIC WELLNESS

August 4th, 2020 - Ryan Allway

DENVER, Aug. 04, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine”), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform. Mindleap™ is working towards contributing to the […]

PsyIndex Weekly Update for July 27 – July 31

August 3rd, 2020 - Ryan Allway

The PsyIndex rose 5.66% last week after a few big moves. Revive Therapeutics soared higher on Friday after the FDA confirmed a Phase III trial for a COVID-19-related product, while Hollister Biosciences moved sharply higher during Wednesday’s session on high volume. Market Performance Weekly Performance: $84.19 (+5.66%) Top Gainers Revive Therapeutics Ltd. (CSE: RVV) (OTC: […]

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

August 3rd, 2020 - Ryan Allway

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory […]

Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness

July 31st, 2020 - Ryan Allway

Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce its partnership with Together We Can Addiction Recovery and Education Society (TWC). TWC is one of Canada’s largest addiction treatment organizations, a […]

Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.

July 31st, 2020 - Ryan Allway

Novamind Ventures Inc. (“Novamind“), a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce that it has closed the acquisitions of Cedar Psychiatry LLC (“Cedar Psychiatry“), a specialized provider of ketamine-assisted psychotherapy and Cedar Clinical Research LLC (“Cedar Clinical Research“), a dedicated research center focused on psychedelic medicines, both based near Salt […]

Why Extracts Are the Key to Plant-based Medicine

July 30th, 2020 - Ryan Allway

  Plants have long been a source of beneficial pharmaceutical compounds, but extraction transformed these plants into the medicines that we know today. With the rapid growth in the cannabis and psychedelic industries, investors may want to keep an eye on extraction companies that have experience in regulated markets. These extracts could pave the way […]

MindMed Completes Dosing 18-MC Phase 1 Study

July 29th, 2020 - Ryan Allway

Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addiction See Official Release Here NEW YORK, July 28, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated […]

Ex-Canopy Growth Geneticist Turns His Focus to Psychedelics

July 29th, 2020 - Ryan Allway

Recently it was announced that ebbu’s Director of Research, Robert Roscow, M.A., would leave a cannabis industry conglomerate to become the Chief Science Officer of the leading psychedelic startup Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE: 0NF). Though the coming and going of executives is commonplace in the corporate world, this latest personnel shakeup has […]

MYDECINE INNOVATIONS GROUP INC. APPOINTS PREVIOUS RED BULL SPORTS MARKETING DIRECTOR JIM GUNNING AS CMO

July 27th, 2020 - Ryan Allway

DENVER, July 24, 2020 /PRNewswire/ — Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) (“Mydecine” or the “Company”), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company’s new Chief Marketing Officer (“CMO”). “When I was first contacted by Damon Michaels, the company’s Chief Operations Officer, regarding the high-level plans for […]

Good2Go Corp. and Magical Brands Inc. Announce Update to Proposed Qualifying Transaction

July 23rd, 2020 - Ryan Allway

Good2Go Corp. (“G2G” or the “Company”) (TSXV: GOTO.P) is pleased to provide an update on its previously announced proposed qualifying transaction (the “Transaction”) involving Magical Brands Inc. (“Magical Brands”). Pursuant to the Transaction, it is intended that the Company will, directly or indirectly, acquire all of the issued and outstanding securities of Magical Brands (the […]

Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 Million

July 23rd, 2020 - Ryan Allway

VANCOUVER, BC, July 22, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce it has entered into an engagement letter with Mackie Research Capital Corporation (the “Agent” or “Mackie“) in connection […]

Nutritional High Announces Closing of Psychedelic Science Corp’s Private Placement of Units

July 22nd, 2020 - Ryan Allway

Nutritional High International Inc. (CSE: EAT) (“Nutritional High” or, the “Company“) is pleased to announce that Psychedelic Science Corp. (“PSC“) has closed a non-brokered private placement (the “Offering“) for aggregate gross proceeds of $1,035,689 through the issuance 34,522,968 units (the “Units“) of PSC at a price of $0.03 per Unit. Each Unit is comprised of one […]

MagicMed Sets Out to Help Partners Develop Pharma-Grade Psychedelics

July 22nd, 2020 - Ryan Allway

The psychedelics industry is projected to grow at a 16.3% compound annual growth rate to reach $6.85 billion, according to Data Bridge Market Research, driven by the increasing prevalence of mental health disorders and a growing acceptance of psychedelic drugs for the treatment of these diseases. With more than 15 publicly traded companies, investors have […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading